TABLE 1.

Combination therapy with PTX plus Bz ameliorates parasite control and electrical abnormalities in chronically T. cruzi-infected mice^a

Parameter	Mean value for treatment group ± SE
	NI	Pretherapy (120 dpi)	Posttherapy (150 dpi)
			Veh	PTX	Bz	Bz+PTX
Parasitemia level (104 parasites/ml)	0	53 ± 10	68 ± 9 ††	64 ± 23 #	16 ± 15 #	14 ± 8 ##,§
Heart parasite load (parasite equivalents/mg)	0	NT	229 ± 69	216 ± 64	10 ± 3 ##	32 ± 22 #,§
% of mice with arrhythmia	0	100 ± 0 ***	100 ± 0 ***	78 ± 8 #,†	76 ± 3 ###,†††	63 ± 6 ###,†††
No. of flutter events/2 min	0	0	38.5 ± 2.1 ***,†††	0 ###	0 ###	0 ###
% of mice with AVB2	0	86 ± 6 ***	86 ± 5 ***	39 ± 0.4 ###,†††	32 ± 0.6 ###,†††	32 ± 4 ###,†††
No. of AVB2 events/2 min	0	212 ± 11 ***	280 ± 8 ***,†††	40 ± 1.4 ###,†††	44 ± 2 ###,†††	50 ± 1.7 ###,†††
Avg HR (bpm)	504 ± 11	439 ± 9 ***	449 ± 13 **	484 ± 14 ††	515 ± 25 #,††	495 ± 17 #,††
QTc (ms)	80 ± 2.5	97.3 ± 3.2 ***	94.8 ± 3 **	86.7 ± 3.6 †	93.5 ± 5.3	79.9 ± 3.5 ##,‡,††

^aNT, not tested; HR, heart rate. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (for comparison of vehicle-infected T. cruzi-infected mice with NI mice). #, P < 0.05; ##, P < 0.01; ###, P < 0.001 (for comparison of T. cruzi-infected mice administered PTX, Bz, or Bz-plus-PTX treatment with Veh-injected infected mice). §, P < 0.05 (for comparison of T. cruzi-infected mice administered Bz-plus-PTX treatment with infected mice treated with PTX). ‡, P < 0.05 (for comparison of T. cruzi-infected mice administered Bz-plus-PTX treatment with infected mice treated with Bz). †, P < 0.05; ††, P < 0.01; †††, P < 0.001 (for comparison of T. cruzi-infected mice administered PTX, Bz, or Bz-plus-PTX treatment with infected mice pretherapy [120 dpi]).